DuLac Farmaceutici, an Italian pharmaceutical company, is accelerating its expansion into the U.S. market with the launch of its products on OneLavi.com and its upcoming participation in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, scheduled for September 14-17 in Palm Beach Gardens, Florida. These initiatives mark a significant step in the company's strategy to broaden its American footprint beyond its existing presence on Amazon.
The company's approach involves building a multi-channel U.S. presence that leverages established consumer demand on Amazon, expands e-commerce availability through OneLavi, and engages directly with retailers and distribution partners at ECRM. According to Gabriele Bollani, Founder and CEO of DuLac Farmaceutici, "ECRM comes at an important time for DuLac because we are making a major commitment to the U.S. market. Amazon has demonstrated that American consumers are responding to our products, OneLavi gives us another important U.S. channel, and now we are ready to introduce DuLac to major retailers and build the partnerships that can take our expansion to the next level."
The company's success on Amazon is notable, with Arnica Gel 98% earning more than 13,000 customer reviews and an average 4.5-star rating, while the Dinaven line has received over 4,000 reviews and maintains a 4.6-star average. These positive consumer responses validate the brand's appeal and provide a strong foundation for further growth. The addition of OneLavi as a distribution partner offers another platform to introduce DuLac's Made in Italy portfolio to American consumers.
At the ECRM session, DuLac will engage in scheduled meetings with buyers from major health, specialty, food, drug, and mass retail channels. This presents an opportunity to showcase its Italian-developed products, pharmaceutical heritage, and advanced manufacturing capabilities. Among the products highlighted will be the high-concentration Arnica Gel 98% range and the Dinaven and Diosmin lines. The company's objective is not just to gain additional points of distribution but to establish relationships that can support a larger and more diversified U.S. retail presence.
DuLac brings over 30 years of pharmaceutical industry expertise and pharmacy-channel experience in Italy to its U.S. expansion. Its capabilities include proprietary Arnica Montana Arricchita™ project, indoor vertical farming, micronized Diosmin MPFF technology, solvent-free Supercritical CO₂ Extraction, and manufacturing under internationally recognized GMP and ISO quality frameworks. This combination of heritage, research, and advanced production technologies positions the company well for its next stage of growth.
With Amazon already established, OneLavi now live, and ECRM meetings planned, DuLac is moving from initial market development toward a broader national expansion strategy. The company aims to build a diversified U.S. presence across e-commerce, retail, wholesale, and other distribution channels, introducing more American consumers to its brand and product portfolio. For more information, visit DuLac Farmaceutici USA or the company's Amazon Storefront and One Lavi.
